Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Section 5 of 6

Economic information and modeling report

55 evidence topics · 38 sources

Modeling overview

Summary: acquisition prices of on-demand agents by price type

  • Wholesale acquisition cost (WAC), oral sebetralstat (Ekterly) 300 mg: $33,440.0000 at introduction on 2025-07-07 for a pack of 4 tablets (California filing); $8,360 per tablet, $16,720 per dose of two tablets, and $33,440 per package of two doses (Missouri Medicaid fact blast, 2025); $35,614 per carton of 4 tablets (KalVista Colorado disclosure, 2026); and $35,614.0000 at introduction on 2026-09-21 for a 4-tablet pack (California filing, 2026).
  • WAC, Berinert 500 units (NDC 63833082502): $3,250.00 effective 01/01/2021, $3,415.75 on 01/01/2022, $3,620.69 on 01/01/2023, $3,837.93 on 01/01/2024, $4,068.20 on 07/01/2024, $4,271.61 on 01/01/2025, and $4,442.47 on 01/01/2026.
  • WAC, Ruconest 2100 U, 1 carton: $7,625.00 effective 01/01/2024 and $8,075.00 effective 01/01/2025.
  • WAC at introduction, generic icatibant and Sajazir: $5,083.26 per single syringe and $15,249.78 per 3 (Teva, 2019-07-15); $5,083.26 per single unit (Cipla, 2020-07-20; Fresenius Kabi, 2020-10-21); $2,795.79 (Apotex, 2021-04-15); $5,000.00 per vial and $15,000.00 per 3 vials (Sajazir, 2021-08-16); $1,000.00 per syringe and $3,000.00 per 3 (AuroMedics, 2025-05-20); $750.00 per vial and $2,250.00 per 3 vials (Alembic, 2025-09-25). The Sajazir manufacturer states that the WAC for Firazyr was $11,147.49 (NDC 54092-0702-02) and that parity with Firazyr was one determining factor of its price; a 2025 generic entrant states that it is launching its product as a lower price generic product.
  • Federal Supply Schedule (FSS) and Big Four prices, 2026 VA file: Firazyr 30 mg/3 mL $9,522.98 FSS and $7,284.86 Big Four per syringe, $28,568.96 FSS and $20,309.55 Big Four per 3; generic icatibant $979.90 and $2,939.70 FSS (Fresenius Kabi, 3 mL and 3 x 3 mL) and $2,317.97 and $6,952.90 FSS (NDCs 00093-3066-34 and 00093-3066-93); Kalbitor 10 mg/mL, 3 x 1 mL, $16,754.10 FSS and $12,431.63 Big Four; Berinert 500 IU vial $3,217.25 FSS and $2,650.06 Big Four; Ruconest 2100 unit vial $4,918.75 FSS and Big Four.
  • Medicare Part B payment limits, October 1 to December 31, 2026, based on 2Q26 ASP data: Berinert (J0597) $79.329 per 10 units with a co-insurance percentage of 18.454; Ruconest (J0596) $37.810 per 10 units and Kalbitor (J1290) $599.616 per 1 mg, each with 20.000.
  • Medicare Part D, 2024: average spending per beneficiary was $257140.16824 for Firazyr (170 beneficiaries), $49357.793951 for generic icatibant (658), $549167.57048 for Berinert (63), $435241.23625 for Ruconest (128), and $579766.23194 for Kalbitor (36).
  • Prices outside the United States, sebetralstat: £12,000 list price for a 300-mg pack of 6 tablets, including VAT, in the English company submission; €17,707.74 pharmacy sales price and €16,697.97 after statutory rebates for 6 film-coated tablets in Germany.
  • Historical per-dose inputs (ICER, 2018): FSS or Big Four price as of September 15, 2018 of $4,174 (Berinert, 20 IU/kg), $11,174 (Kalbitor, 30 mg), $7,178 (Firazyr, 30 mg), and $10,112 (Ruconest, 50 IU/kg); average sales price as of June 13, 2018 plus a 9% markup of $9,807, $15,594, $7,178, and $15,164.

Summary: cost per attack, redosing, and cost of illness

  • Cost per attack: the 2018 ICER report states that on-demand medications range in cost from $5,000 to more than $12,000 per attack treated in the US. In an Italian cohort analyzed from the Italian National Health Service perspective, 1190 of the attacks (78.9%) were treated on demand, 704 with pdC1-INH and 486 with icatibant; the average cost per attack was €1183 (SD €789), the unadjusted mean was €1069 (SD €470) with pdC1-INH and €1651 (SD €469) with icatibant, and after controlling for attack site and severity the icatibant cost remained 54% higher.
  • Redosing: the Missouri Medicaid fact blast reports redosing in 13% to 38% of episodes with sebetralstat, 7% to 44% with icatibant, 8% to 30% with Berinert, 6% to 18% with Kalbitor, and 2% to 10% with Ruconest. The ICER model used extra-dose percentages of 1.9% (Berinert), 12.0% (Kalbitor), 12.7% (Firazyr), and 6.6% (Ruconest), and assumed equal proportions of attacks treated with each drug in each setting.
  • Acute care unit costs in the ICER model: home nurse $177, physician office administration $262, ED visit $1,479 (95% CI: $1,028-$1,929), and hospitalization $4,760 (95% CI: $3,612-$5,907); indirect costs per attack of $959 for mild, $4,048 for moderate, and $6,656 for severe attacks.
  • Annual costs: modeled on-demand-only treatment in a patient survey carried direct costs of $363,795 and indirect costs of $52,576 per patient per year, with medications at $227,674 (62.5%), hospitalization at 22.1%, and ED visits at 12.5%. In claims data, per patient per year costs before and after starting long-term prophylaxis were $165,348 and $515,333 in total, with on-demand pharmacy costs of $217,857 and $167,462 and long-term prophylaxis pharmacy costs of $0 and $395,845 among patients with at least 1 claim; 67% had at least 1 post-index on-demand therapy claim.
  • Self-administration: a Spanish one-year cost-minimization model estimated average savings of €121.30 per acute attack from the social perspective for its strategy 2, and annual savings of €551,371 for Spain.

Summary: published cost-effectiveness analyses of on-demand agents and their inputs

  • A US commercial payer decision-tree model (costs dated to 2019) of ecallantide, icatibant, pdC1-INH, and rhC1-INH estimated costs and effectiveness per attack of $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide. Using 26.9 attacks per person-year, cost per QALY was $420,941, $488,349, $483,892, and $689,773, respectively, and the authors report rhC1-INH as the dominant option.
  • A Polish one-year discrete event simulation from the healthcare payer's perspective compared conestat alfa and plasma-derived C1 inhibitor with placebo: QALY gains of 0.0261 and 0.0262, incremental costs of approximately EUR 419 for a single attack treated with conestat alfa and approximately EUR 755 per patient for human C1-INH, and median incremental cost-utility ratios of EUR 15,226 and EUR 27,786 per QALY against a threshold of EUR 24,279 (PLN 99,543) per QALY.
  • The 2018 ICER prophylaxis model assumed on-demand treatment for acute attacks in the comparator arm and computed average costs per attack weighted by the proportion of attacks treated with each drug in each setting.
  • No published cost-effectiveness analysis of deucrictibant was identified.

Summary: utility weights for attack and attack-free states

  • US on-demand decision model: 0.51 when experiencing attack symptoms and 0.83 without symptoms.
  • ICER 2018 model: attack-free EQ-5D utility of 0.825 ± 0.207, with disutilities of 0.070, 0.369, and 0.486 for mild, moderate, and severe attacks.
  • European survey mapped to UK EQ-5D weights (111 participants): 0.44 during an attack and 0.72 between attacks; 0.61, 0.47, and 0.08 for no or mild, moderate, and severe pain during the last attack.
  • US survey (KalVista-funded): EQ-5D-5L index of 0.849 today and 0.568 during the last treated attack in the treated cohort, 0.667 when treated within 1 hour of onset and 0.504 when treated 5 to less than 8 hours after onset, and 0.859 today and 0.661 during the last untreated attack in the untreated cohort.
  • Time trade-off with the general public in England (BioCryst-funded): attack-free 0.783, hand 0.582, facial 0.483, abdominal 0.345, laryngeal 0.128, and caregiver 0.762.
  • A US qualitative study of 25 adults with HAE concluded that severity definitions for evaluating new treatments should incorporate attack location, symptoms, and phase.

Summary: health technology assessments of oral on-demand sebetralstat

  • England: the NICE draft guidance states that sebetralstat should not be used to treat HAE attacks in people 12 years and over and that the most likely cost-effectiveness estimates cannot be determined. The company base-case ICER against a basket of treatments was “considerably higher than £30,000 per QALY gained”; exact ICERs are confidential. KONFIDENT did not collect health-related quality of life data, utilities were informed by the Lo et al. (2022) time trade-off analysis, and the company base case applied no disutility difference between subcutaneous and oral administration. The 2026 project page states that NICE paused publication of the draft guidance due to exceptional circumstances, that an updated commercial offer has been agreed, that publication of the final draft guidance is paused until mid-November, and that sebetralstat remains available through the EAMS plus route.
  • Germany: the G-BA found a “hint for a non-quantifiable additional benefit”, noted that no health-related quality of life data were collected, and costed 1 or 2 doses per attack at one attack every three weeks to one attack every week.
  • France: the HAS transparency committee, on 22 April 2026, rated the medical benefit (SMR) of Ekterly as important and its added benefit as ASMR V, and estimated about 1 850 patients with HAE in France and a target population of 1 600.

Summary: payer utilization management of on-demand agents

  • Cigna (review date 07/08/2026): Ekterly quantity limits sufficient to treat 4 attacks at the maximum dose per 28 days, assuming two 600 mg doses in 24 hours per attack, with an override for an additional 4 attacks each month.
  • Univera Healthcare: for patients 18 years and older, Ekterly requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant, with a quantity limit of 4 tablets per 30 days; brand Firazyr requires the same documentation regarding generic icatibant; quantity limits of 3 pre-filled syringes (9 mL) per 30 days and 10 vials per 30 days on the prescription benefit appear in the policy; one acute HAE medication is authorized at one time.
  • Regence (effective April 1, 2026): documentation that generic icatibant and at least one of Berinert or Ruconest have been ineffective, not tolerated, or contraindicated; acute treatments authorized in a quantity sufficient for three attacks per month; generic icatibant described as the lowest cost of all available options.
  • CountyCare medical benefit: lists Berinert (J0597), Firazyr (J1744), Kalbitor (J1290), and Ruconest (J0596), and requires trial and failure or intolerance of the preferred product for non-preferred requests.
  • MO HealthNet: Ekterly prior authorization for on-demand treatment of acute HAE attacks with an initial approval period of 6 months; the fact blast lists deucrictibant with a phase III trial (NCT06669754) and an estimated completion of August 2026; the sponsor identifies NCT06669754 as CHAPTER-3, its trial of deucrictibant XR for prophylaxis.

Summary: population, market size, and company statements

  • US population: claims-based estimates of 9559, 9341, and 8694 people diagnosed with HAE in 2018, 2019, and 2020, and expert physician estimates of 7602, 7275, and 6595 (Castaldo et al. (2025)); fewer than 8000 people in the United States with HAE due to C1 inhibitor deficiency (Castaldo et al. (2021)); and, as a company statement citing HAE International as of October 2014, at least 7,000 patients in the U.S. and at least 15,000 in the EU (Pharvaris 20-F).
  • Treatment pattern: 37.3% (n = 275) of 737 survey respondents used on-demand-only treatment; approximately 70% of US patients with HAE are treated with long-term prophylaxis (Tachdjian et al. (2026)).
  • Payer mix: The California filing for sebetralstat states a payer mix of 70% commercial payors, 25% Medicare Part D, and 5% Medicaid, with estimated patient numbers of 780 (2025 filing) and 7500 (2026 filing).
  • Market size: Pharvaris states that global sales of HAE treatments in 2024 were estimated at approximately $2.7 billion and, according to public research reports, are forecast to reach $4.7 billion through 2036; an ADARx prospectus cites approximately $3.12 billion in 2024 and approximately $6.83 billion by 2032 (Evaluate Pharma).
  • Company statements: Pharvaris states a median of 14 attacks per year according to scientific publications, expects its product candidates, if approved, to be priced at a “significant premium over competitive generic products”, and expects generic products to create potential pricing pressure. Its third quarter 2026 discussion attributes expenses to pricing research and HAE market data supporting a potential launch of IR in 2027, and expects revenues from sales in 2027 if deucrictibant IR is approved by the FDA.

Wholesale acquisition cost of Ruconest, 2024 and 2025

Wholesale acquisition cost of generic icatibant and Sajazir at introduction, 2019 to 2025

Federal Supply Schedule and Big Four prices of on-demand agents, November 2026

ProductPackageNDCPackage sizePrice typePrice ($)
Icatibant (Firazyr)“FIRAZYR 30MG/3ML INJECTION”“54092-0702-02”“1”“Big4”“7284.86”
Icatibant (Firazyr)“FIRAZYR 30MG/3ML INJECTION”“54092-0702-02”“1”“FSS”“9522.98”
Icatibant (Firazyr)“FIRAZYR 30MG/3ML INJECTION”“54092-0702-03”“3”“Big4”“20309.55”
Icatibant (Firazyr)“FIRAZYR 30MG/3ML INJECTION”“54092-0702-03”“3”“FSS”“28568.96”
Icatibant (generic, Fresenius Kabi)“ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML”“63323-0574-86”“3ML”“FSS”“979.90”
Icatibant (generic, Fresenius Kabi)“ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML”“63323-0574-93”“3X3ML”“FSS”“2939.70”
Icatibant (generic, AvKare)“ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML”“00093-3066-34”“3ML”“FSS”“2317.97”
Icatibant (generic, AvKare)“ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML”“00093-3066-93”“3X3ML”“FSS”“6952.90”
Ecallantide (Kalbitor)“KALBITOR 10MG/ML INJ”“47783-0101-01”“3X1ML”“Big4”“12431.63”
Ecallantide (Kalbitor)“KALBITOR 10MG/ML INJ”“47783-0101-01”“3X1ML”“FSS”“16754.10”
C1 esterase inhibitor, plasma-derived (Berinert)“BERINERT C1 INHIBITOR 500 IU/VIL”“63833-0825-02”“1”“Big4”“2650.06”
C1 esterase inhibitor, plasma-derived (Berinert)“BERINERT C1 INHIBITOR 500 IU/VIL”“63833-0825-02”“1”“FSS”“3217.25”
C1 esterase inhibitor, recombinant (Ruconest)“RUCONEST 2100UNITS/VIL INJ,PWDR”“71274-0350-02”“1”“Big4”“4918.75”
C1 esterase inhibitor, recombinant (Ruconest)“RUCONEST 2100UNITS/VIL INJ,PWDR”“71274-0350-02”“1”“FSS”“4918.75”

Medicare Part D spending on on-demand agents, 2024

BrandTotal spending, 2024 ($)Beneficiaries, 2024Average spending per dosage unit, 2024 ($)Average spending per beneficiary, 2024 ($)
Firazyr (icatibant)“43713828.6”“170”“3553.9698049”“257140.16824”
Icatibant (generic)“32477428.42”“658”“955.46002803”“49357.793951”
Berinert (C1 esterase inhibitor)“34597556.94”“63”“3904.4754475”“549167.57048”
Ruconest (recombinant C1 esterase inhibitor)“55710878.24”“128”“7557.0914596”“435241.23625”
Kalbitor (ecallantide)“20871584.35”“36”“5624.2480059”“579766.23194”

Redosing rates of on-demand agents reported in a new drug fact blast for a state Medicaid program

ProductRedosing rates reported (share of episodes)
Sebetralstat (Ekterly)“13%–38% of”
Icatibant (Firazyr, Sajazir)“7%–44% of”
C1 esterase inhibitor, plasma-derived (Berinert)“8%–30% of”
Ecallantide (Kalbitor)“6%–18% of”
C1 esterase inhibitor, recombinant (Ruconest)“2%–10% of episodes”

On-demand drug cost inputs per dose in a published US prophylaxis model

ParameterBerinertKalbitorFirazyrRuconest
Dose schedule“20 IU/kg”“30 mg”“30 mg”“50 IU/kg”
FSS per dose“$4,174”“$11,174”“$7,178”“$10,112”
ASP per dose“$9,807”“$15,594”“$7,178”“$15,164”
Percentage requiring extra dose“1.9%”“12.0%”“12.7%”“6.6%”

Cost-effectiveness of on-demand recombinant and plasma-derived C1 inhibitor, icatibant, and ecallantide: US decision-tree model

“To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Four on-demand HAE treatments were included: ecallantide, icatibant, plasma-derived (pd)C1-INH, and recombinant human (rh)C1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Cost per QALY was calculated using 26.9 attacks per person-year, leading to results of $420,941 for rhC1-INH, $488,349 for icatibant, $483,892 for pdC1-INH, and $689,773 for ecallantide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Results from this model indicate that rhC1-INH is the dominant treatment option with lower expected costs and higher calculated effectiveness than comparators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Cost-utility of conestat alfa and plasma-derived C1 esterase inhibitor versus placebo: Polish discrete event simulation

“The cost-utility analysis from the Polish healthcare payer's perspective was performed for 1 year (2012).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The incremental costs of each intervention compared with placebo were listed together (direct or indirect comparisons between options were impossible due to limited clinical data available).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Discrete event simulation (DES) is one way of observing the time-dependent (or dynamic) behavior of a system” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Time horizon was set at one year, which seemed to be a reasonable compromise between the short clinical trials observation time and the median life expectancy horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the base case analysis with a one year's perspective, patients with HAE suffering from life-threatening angioedema attacks gained on average 0.0261 quality adjusted life years (QALY) when treated with Ruconest® (conestat alfa) and 0.0262 QALY when treated with Berinert® P compared with placebo (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The incremental costs of the therapy of a single acute angioedema attack with conestat alfa amounted to app. EUR 419, app. EUR 755 per patient for human C1-INH treatment in comparison with placebo, thus indicating that conestat alfa is the cheapest option (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median incremental cost-utility ratios for assessed interventions compared with placebo were as follows: EUR 15,226 per QALY (conestat alfa) and EUR 27,786 per QALY (human C1 esterase inhibitor)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The cost-utility of the therapy was assumed when the ICUR was lower than EUR 24,279 (PLN 99,543) per QALY, which is set as threshold acceptability in Poland (tripled GDP per capita)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.